Ajay Major, Founder and President of Pager Publications and Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:
“BOVen in older first-line mantle cell lymphoma (ASH25)
– 50 patients, median age 72 years, 28% TP53 mutated
– Overall response rate 98% (complete response 94%)
– 2-year progression-free survival 86%, overall survival 92%
– 37% grade 3 or higher infections; 5 deaths: 2 due to disease
– Of 30 patients completing cycle 24, 80% undetectable minimal residual disease at 6 months and stopped treatmen
High infections (risk of obinu in older adults); why not Rituximab?”
More posts from ASH25.